BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37404304)

  • 21. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
    Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
    Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.
    Nallandhighal S; Vince R; Karim R; Groves S; Stangl-Kremser J; Russell C; Hu K; Pham T; Cani AK; Liu CJ; Zaslavsky A; Mehra R; Cieslik M; Morgan TM; Palapattu GS; Udager AM; Salami SS
    Eur Urol Oncol; 2022 Feb; 5(1):92-99. PubMed ID: 34840106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
    Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
    Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of miRNA-lncRNA-mRNA co-expression network affecting EMT-mediated cisplatin resistance in ovarian cancer.
    Naghsh-Nilchi A; Ebrahimi Ghahnavieh L; Dehghanian F
    J Cell Mol Med; 2022 Aug; 26(16):4530-4547. PubMed ID: 35810383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
    Xiong C; Wang G; Bai D
    Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective.
    Zhang Y; Wang X; Chen X
    Aging (Albany NY); 2021 Jan; 13(2):3112-3145. PubMed ID: 33493131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.
    Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D
    Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
    Zhang P; He M; Zeng Y; Cai X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
    Kuznetsov VA; Tang Z; Ivshina AV
    BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway.
    Luo M; Zhou L; Zhan SJ; Cheng LJ; Li RN; Wang H; Liu B; Linghu H
    Biochem Biophys Res Commun; 2019 May; 513(2):528-533. PubMed ID: 30979497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasculogenic mimicry regulates immune infiltration and mutational status of the tumor microenvironment in breast cancer to influence tumor prognosis.
    Zheng S; Guo G; Yang Z; Lu Y; Lu K; Fu W; Huang Q
    Environ Toxicol; 2024 May; 39(5):2948-2960. PubMed ID: 38308456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
    Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
    Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.
    Wang P; Chen Y; Zheng Y; Fu Y; Ding Z
    Dis Markers; 2021; 2021():5340240. PubMed ID: 34712369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers.
    Li QJ; Wu ZL; Wang J; Jiang J; Lin B
    J Ovarian Res; 2023 Mar; 16(1):51. PubMed ID: 36907877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
    Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
    Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Kar SP; Adler E; Tyrer J; Hazelett D; Anton-Culver H; Bandera EV; Beckmann MW; Berchuck A; Bogdanova N; Brinton L; Butzow R; Campbell I; Carty K; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Dansonka-Mieszkowska A; Doherty JA; Dörk T; Dürst M; Eccles D; Fasching PA; Flanagan J; Gentry-Maharaj A; Glasspool R; Goode EL; Goodman MT; Gronwald J; Heitz F; Hildebrandt MA; Høgdall E; Høgdall CK; Huntsman DG; Jensen A; Karlan BY; Kelemen LE; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Lambrechts D; Levine DA; Li Q; Lissowska J; Lu KH; Lubiński J; Massuger LF; McGuire V; McNeish I; Menon U; Modugno F; Monteiro AN; Moysich KB; Ness RB; Nevanlinna H; Paul J; Pearce CL; Pejovic T; Permuth JB; Phelan C; Pike MC; Poole EM; Ramus SJ; Risch HA; Rossing MA; Salvesen HB; Schildkraut JM; Sellers TA; Sherman M; Siddiqui N; Sieh W; Song H; Southey M; Terry KL; Tworoger SS; Walsh C; Wentzensen N; Whittemore AS; Wu AH; Yang H; Zheng W; Ziogas A; Freedman ML; Gayther SA; Pharoah PD; Lawrenson K
    Br J Cancer; 2017 Feb; 116(4):524-535. PubMed ID: 28103614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
    Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
    Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.